Clinical and Laboratory Features in the Israeli Population with COVID-19 Infection after Pfizer-BioNTech mRNA Booster Vaccination.

ABSTRACT:

Background

Immune protection following either vaccination or infection with SARS-CoV-2 decreases over time.

Objective

We aim to describe clinical and sociodemographic characteristics associated with COVID-19 infection at least 14 days after booster vaccination in the Israeli population.

Methods

We conducted a population-based study among adult members of Leumit Health Services (LHS) in Israel. Nasopharyngeal swabs were examined for SARS-CoV-2 by real-time RT-PCR. The hematological and biochemical parameters in the peripheral blood before booster vaccination were evaluated.

Results

Between 1 February 2021 and 30 November 2021, 136,683 individuals in LHS were vaccinated with a booster (third dose) of the BNT162b2 vaccine. Of these, 1171 (0.9%) were diagnosed with

SUBMITTER: Israel A 

PROVIDER: S-EPMC9145987 | biostudies-literature | 2022 Apr

REPOSITORIES: biostudies-literature